Zhihai Si

Zhihai Si has a diverse and extensive work experience spanning over several companies. Starting in 1998 at Dana-Farber Cancer Institute, they worked as a Scientist and later as a Postdoctoral Fellow, conducting research on the antibody neutralization resistance of viral surface proteins and the structural basis of resistance of viral envelope glycoprotein to antibody neutralization. From 2004 to 2010, they worked at Harvard Medical School as an Instructor, where they designed and executed cell-based assays, created a novel fusion protein, and elucidated the mechanism of an entry inhibitor in HIV-1 envelope glycoproteins. Zhihai then joined Roche in 2010 as a Research Scientist, focusing on TaqMan-based multiplex quantitative real-time PCR (qPCR) assay development and nucleic acid isolation and purification. In 2011, Zhihai joined Histogenics Corporation as a Senior Scientist, developing and qualifying cell-based and biochemical assays, investigating immunological properties of chondrocytes, and refining cell therapy processes. From 2016 to 2017, they worked at Biostage, Inc. as a Senior Scientist, developing assays to assess potency and immunomodulatory properties of stem cells, and contributing to FDA pre-IND filings. At Akebia Therapeutics from 2017 to 2021, Zhihai served as a Senior Scientist, drafting study reports for NDA filings and managing multiple projects. Zhihai is currently working at Ultragenyx as the Director of Quality Control. Overall, Zhihai Si has extensive experience in quality control, research and development, assay development, and project management in the pharmaceutical and biotechnology industries.

Zhihai Si holds a Ph.D. in Microbiology and Virology from the University of Iowa College of Medicine. In addition, Zhihai Si has obtained certifications in "Communicating In the Language of Leadership" and "Delegating Tasks" from LinkedIn in the year 2020.